- Clearmind Medicine has completed a Type A meeting with the U.S. Food and Drug Administration for its clinical trial of CMND-100 to treat alcohol use disorder
- The active ingredient in CMND-100 is MEAI, which is a psychoactive molecule shown to reduce the desire to consume alcoholic beverages while providing an alcohol-like experience
- The company can now work towards advancing the U.S. regulatory process of CMND-100
- Shares of Clearmind Medicine are up 38.32 per cent to C$3.79 as of 11:01 am ET
Clearmind Medicine (CSE:CMND) is set to advance its alcohol use disorder treatment (AUD) after a Type A meeting with the U.S. Food and Drug Administration (FDA).
In a news release, the biotech company focused on the discovery and development of novel psychedelic-derived therapeutics stated the meeting discussed Clearmind Medicine’s clinical trial of CMND-100 compound, which has the active ingredient MEAI, a novel psychoactive molecule.
The company stated CMND-100 aims to treat AUD by reducing the desire to consume alcoholic beverages while providing an alcohol-like experience.
“The meeting was informative and productive, and we’re eager to advance the U.S. regulatory process and potentially bring a new hope for millions suffering from AUD by providing an innovative approach to overcome the challenges associated with the current available treatments to date,” Adi Zuloff-Shani, CEO of Clearmind Medicine, said in a statement.
Additionally, MEAI interacted well with the serotonergic receptors that will play an integral role in regulating alcohol intake, reward, preference and dependence.
MEAI aims to break binge-drinking cycles by innervating neural pathways such as 5-HT1A, which has been found to decrease impulsivity and “sensible” behaviour.
Clearmind Medicine’s intellectual portfolio includes 15 patent families and intends to seek additional patents for its compounds.
The company aims to develop and treat underserved health problems, including AUD.
Shares of Clearmind Medicine are up 44.89 per cent to C$3.97 as of 11:58 a.m. ET.
Join the discussion: Find out what everybody’s saying about this stock on the Clearmind Medicine Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.